quinazolines has been researched along with Diabetic Nephropathies in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (5.56) | 29.6817 |
| 2010's | 17 (94.44) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Han, J; Liang, G; Qian, Y; Wang, J; Weng, Q; Xu, Z; Zhao, Y; Zhong, P; Zou, C | 1 |
| Barnett, AH; Lewin, AJ; McGill, JB; Neubacher, D; Patel, S; von Eynatten, M; Woerle, HJ | 1 |
| He, J; Ishigaki, Y; Kanasaki, K; Kanasaki, M; Kitada, M; Koya, D; Nagai, T; Nakamura, Y; Shi, S; Srivastava, SP | 1 |
| Crowe, S; Del Prato, S; Gong, Y; Groop, PH; Owens, DR; Patel, S; Taskinen, MR; von Eynatten, M; Woerle, HJ | 1 |
| Harris, RC; Paueksakon, P; Wang, Y; Zhang, MZ | 1 |
| Matsui, T; Nakashima, S; Takeuchi, M; Yamagishi, SI | 1 |
| Panchapakesan, U; Pollock, CA | 1 |
| Hirata, T; Ito, T; Kurita, N; Shimizu, S; Uchihara, H | 1 |
| Barnett, AH; Gallwitz, B; Groop, PH; Hehnke, U; Laakso, M; Patel, S; Rosenstock, J; Tamminen, I; von Eynatten, M; Woerle, HJ | 1 |
| Cooper, ME; Groop, PH; Hehnke, U; McGill, JB; Perkovic, V; Rosenstock, J; von Eynatten, M; Wanner, C; Woerle, HJ | 1 |
| Gao, B; Gilbert, RE; Ingram, AJ; Kelly, DJ; Krepinsky, JC; Kumar, S; Peng, F; Wu, D; Zhang, B | 1 |
| Aoki, T; Enomoto, R; Kaneko, S; Matsuoka, N; Shimoshige, Y | 1 |
| Barnett, AH | 1 |
| Friedrich, C; Graefe-Mody, U; Halabi, A; Heise, T; Port, A; Retlich, S; Ring, A; Woerle, HJ | 1 |
| Doogue, MP; Polasek, TM; Snyder, B | 1 |
| Somogyi, A | 1 |
| Alter, ML; Henze, A; Hocher, B; Klein, T; Krause-Relle, K; Ott, IM; Raila, J; Sharkovska, Y; Tsuprykov, O; von Websky, K | 1 |
| Bakris, GL; Flynn, C | 1 |
5 review(s) available for quinazolines and Diabetic Nephropathies
| Article | Year |
|---|---|
Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment.
Topics: Adult; Aged; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Male; Middle Aged; Placebos; Purines; Quinazolines; Randomized Controlled Trials as Topic; Severity of Illness Index | 2014 |
Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes.
Topics: Aged; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Linagliptin; Male; Middle Aged; Purines; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2015 |
Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy.
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Linagliptin; Purines; Quinazolines | 2011 |
[Oral antidiabetic drugs in chronic renal disease].
Topics: Administration, Oral; Blood Glucose; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Hypoglycemic Agents; Linagliptin; Pioglitazone; Purines; Quinazolines; Thiazolidinediones | 2012 |
Noninsulin glucose-lowering agents for the treatment of patients on dialysis.
Topics: Adamantane; Biguanides; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Glucagon-Like Peptides; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Linagliptin; Meglumine; Metformin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Dialysis; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Uracil; Vildagliptin | 2013 |
2 trial(s) available for quinazolines and Diabetic Nephropathies
| Article | Year |
|---|---|
Linagliptin added to sulphonylurea in uncontrolled type 2 diabetes patients with moderate-to-severe renal impairment.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Monitoring; Drug Resistance; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Kidney; Linagliptin; Male; Middle Aged; Purines; Quinazolines; Renal Insufficiency, Chronic; Retrospective Studies; Severity of Illness Index; Sulfonylurea Compounds | 2014 |
Treatment with the dipeptidyl peptidase-4 inhibitor linagliptin or placebo followed by glimepiride in patients with type 2 diabetes with moderate to severe renal impairment: a 52-week, randomized, double-blind clinical trial.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Male; Purines; Quinazolines; Sulfonylurea Compounds | 2015 |
11 other study(ies) available for quinazolines and Diabetic Nephropathies
| Article | Year |
|---|---|
EGFR inhibition attenuates diabetic nephropathy through decreasing ROS and endoplasmic reticulum stress.
Topics: Animals; Cell Line; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Endoplasmic Reticulum Stress; ErbB Receptors; Humans; Mice; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Reactive Oxygen Species; Streptozocin; Transforming Growth Factor beta; Tyrphostins | 2017 |
Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen.
Topics: Animals; Blotting, Western; Cell Line, Transformed; Cell Proliferation; Cells, Cultured; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Down-Regulation; Endothelial Cells; Fibrosis; Gene Expression Regulation; Genetic Pleiotropy; Immunohistochemistry; Linagliptin; Male; Mesenchymal Stem Cells; Mice; Mice, Inbred NOD; MicroRNAs; Purines; Quinazolines; Streptozocin | 2014 |
Epidermal growth factor receptor inhibition slows progression of diabetic nephropathy in association with a decrease in endoplasmic reticulum stress and an increase in autophagy.
Topics: Albuminuria; AMP-Activated Protein Kinases; Animals; Apoptosis; Autophagy; Blood Glucose; Blood Pressure; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Progression; Endoplasmic Reticulum Stress; ErbB Receptors; Erlotinib Hydrochloride; Immunohistochemistry; Kidney; Mice; Mice, Inbred NOD; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2014 |
Linagliptin blocks renal damage in type 1 diabetic rats by suppressing advanced glycation end products-receptor axis.
Topics: Animals; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Dipeptidyl Peptidase 4; Glycation End Products, Advanced; Humans; Intercellular Adhesion Molecule-1; Kidney; Linagliptin; Male; Purines; Quinazolines; Rats; Rats, Sprague-Dawley; Receptor for Advanced Glycation End Products; Receptors, Immunologic | 2014 |
DPP-4 inhibitors-renoprotection in diabetic nephropathy?
Topics: Animals; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Endothelial Cells; Linagliptin; Male; Mesenchymal Stem Cells; Purines; Quinazolines | 2014 |
Idiosyncratic liver injury induced by vildagliptin with successful switch to linagliptin in a hemodialyzed diabetic patient.
Topics: Adamantane; Aged; Chemical and Drug Induced Liver Injury; Diabetes Mellitus; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Linagliptin; Nitriles; Purines; Pyrrolidines; Quinazolines; Renal Dialysis; Vildagliptin | 2014 |
EGFR-PLCgamma1 signaling mediates high glucose-induced PKCbeta1-Akt activation and collagen I upregulation in mesangial cells.
Topics: Animals; Blood Glucose; Cells, Cultured; Collagen Type I; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Enzyme Activation; Enzyme Inhibitors; ErbB Receptors; Estrenes; Female; Male; Mesangial Cells; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phospholipase C gamma; Phosphorylation; Protein Kinase C; Protein Kinase C beta; Proto-Oncogene Proteins c-akt; Pyrrolidinones; Quinazolines; Rats; Rats, Sprague-Dawley; RNA Interference; Tyrphostins; Up-Regulation | 2009 |
The involvement of aldose reductase in alterations to neurotrophin receptors and neuronal cytoskeletal protein mRNA levels in the dorsal root ganglion of streptozotocin-induced diabetic rats.
Topics: Aldehyde Reductase; Animals; Cytoskeletal Proteins; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Enzyme Inhibitors; Ganglia, Spinal; Male; Nerve Tissue Proteins; Neurofilament Proteins; Neurons; Polymers; Quinazolines; Rats; Receptors, Nerve Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tubulin | 2010 |
Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*).
Topics: Analysis of Variance; Area Under Curve; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Kidney Failure, Chronic; Linagliptin; Male; Middle Aged; Purines; Quinazolines; Treatment Outcome | 2011 |
Reply to: Graefe-Mody U, Friedrich C, Port A et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab 2011; 13: 939-946.
Topics: Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Kidney Failure, Chronic; Male; Purines; Quinazolines | 2012 |
DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Benzoates; Blood Pressure; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Dipeptidyl Peptidase 4; Disease Models, Animal; Drug Therapy, Combination; Enzyme Inhibitors; Linagliptin; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Nitric Oxide Synthase Type III; Oxidative Stress; Purines; Quinazolines; Streptozocin; Telmisartan; Treatment Outcome | 2012 |